The bioT3 Platform

Ralph V. Boccia, MD, FACP

Video Categories: PMO Interview with the Innovator Series: Volume 9

Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.
July 29, 2015

Incorporating Value and Cost-Awareness in Drug Development

Dr. Jorge Cortes ponders the cost of treatment versus the improvement in the standard of care, asking if what we are gaining is really worth the rising cost.

December 3, 2013

Management of Patients with Basal Cell Carcinoma not Eligible for Surgery or Radiation

In this second clinical commentary entitled, Management of Patients with Basal Cell Carcinoma not Eligible for Surgery or Radiation, Joel Claveau, MD, CSPQ, FRCPC; Dirk Schadendorf, MD; Nicole Basset-Seguin, MD, PhD and Aleksandar Sekulic, MD, PhD discuss the need for new treatment options in the care of basal cell carcinoma [ Read More ]